The Orthobiologics Market is being driven by Increasing prevalence of orthopedic disorders coupled with an aging population
The Orthobiologics Market is expected to grow at a CAGR of 7.75% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2768 million. The Orthobiologics Market is witnessing a significant trend of continuous new product development, driven by substantial investments in research and development. This innovation wave will motivate competitors to introduce advanced products to stay competitive in the market. Notably, SeaSpine recently launched the NorthStar cervical facet fusion and Flash navigation lumbar facet fusion systems in March 2022. These orthobiologic systems, featuring OsteoStrand demineralized bone matrix (DBM) fibers, streamline procedural workflows and maximize fusion areas, setting new industry standards. These product launches are expected to bolster market revenue during the forecast period.
Get more information on Orthobiologics Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
180 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.75% |
Market growth 2024-2028 |
USD 2768 million |
Market structure |
market_structure.ucfirst |
YoY growth 2023-2024(%) |
7.19 |
Key countries |
US, UK, Germany, Canada, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Orthobiologics Market encompasses innovative treatments utilizing Decellularized Matrix, Extracellular Matrix, Bone Marrow Concentrate, Platelet-Rich Fibrin, Adipose-Derived Stem Cells, and Mesenchymal Stem Cells for addressing various conditions such as Osteochondral Defects, Ligament Injuries, Tendon Injuries, Rotator Cuff Tears, ACL Tears, Rheumatoid Arthritis, Spinal Fusion, Craniofacial Reconstruction, Dental Implants, Periodontal Disease, Burn Wounds, Diabetic Foot Ulcers, Chronic Wounds, Post-Surgical Recovery, Tissue Viability, and more. Advanced techniques like Cell Culture, Cell Expansion, and Quality Control ensure product efficacy. Regulatory Affairs, Clinical Practice Guidelines, Evidence-Based Medicine, Cost-Benefit Analysis, Value-Based Healthcare, Patient-Centered Care, Multidisciplinary Approach, Health Economics, Health Policy, and Healthcare Reform shape the market landscape. Modern technologies like Remote Monitoring, Wearable Technology, Machine Learning, and Predictive Analytics revolutionize biologics and cell therapy manufacturing.
The Orthobiologics Market, a segment of the larger global biotechnology industry, encompasses businesses specializing in the research and development or production of Platelet-Rich Plasma (PRP), Stem Cell Therapy, Tissue Grafts, Growth Factors, Regenerative Medicine, Tissue Engineering, and Cellular Therapy. According to Technavio, the global healthcare market, which includes the revenues of Orthobiologics Market players, is anticipated to expand significantly due to demographic shifts. By 2050, approximately one-quarter of the US population and by 2030 in Europe, are projected to be over 60 years old. This aging population trend will fuel market growth for Orthobiologics and other healthcare solutions.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted